Henry Schein, Inc.
HSIC Healthcare Medical Distribution
Henry Schein, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $13.2 billion, up 4.03% from fiscal 2024. In the quarter to June 2026, revenue grew 6.73%, EPS grew 16.9%, free cash flow grew 140.9% and total debt rose 15.2%, each against the same quarter a year earlier. Member of the S&P 500; insiders bought in the last twelve months.
Follow HSIC
Henry Schein, Inc. (HSIC) Return on equity
Henry Schein, Inc.'s return on equity over the twelve months to 30 June 2026 was 10.2%, up 0.2 percentage points from fiscal 2025 (10.0%). Over the past ten years it has ranged from 9.38% (fiscal 2024) to 19.4% (fiscal 2019); the current reading is higher than 27% of that period. That is above the Medical Distribution industry median of 0.00% and above the Healthcare sector median of −31.3%.
Return on equity, annual
Embed this chart
Annual newest first
| Period | Return on equity | Change (points) |
|---|---|---|
| FY2025 | 10.0% | 0.66 |
| FY2024 | 9.38% | (0.54) |
| FY2023 | 9.92% | (3.27) |
| FY2022 | 13.2% | (2.49) |
| FY2021 | 15.7% | 5.07 |
| FY2020 | 10.6% | (8.76) |
| FY2019 | 19.4% | 2.53 |
| FY2018 | 16.8% | 2.39 |
| FY2017 | 14.5% | (3.37) |
| FY2016 | 17.8% | 1.02 |
Against its own ten years
Return on equity against peers
| Company | Return on equity |
|---|---|
| COR Cencora, Inc. compare | 96.3% |
| ACH Accendra Health, Inc. compare | 72.6% |
| HSIC Henry Schein, Inc. | 10.2% |
| AHG Akso Health Group Sponsored ADR compare | 0.00% |
| HKPD Cellyan Biotechnology Co., Ltd compare | 0.00% |
| CAH Cardinal Health, Inc. compare | −64.0% |
| COSM Cosmos Health Inc. compare | −104.0% |
| FOCL FocalTherics compare | −133.5% |
| MCK McKesson Corporation compare | −168.5% |
| Medical Distribution industry median | 0.00% |
| Healthcare sector median | −31.3% |
| Market median | 1.35% |
What Return on equity is
ROE shows how much profit a company earns for its shareholders on the equity they have in the business.
Annual: Net Income Allotted to Shareholders ÷ Average Common Equity; TTM: Net Income Allotted to Shareholders ÷ Average Common Equity (latest quarter)
More on HSIC
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement